Whole Body Periodic Acceleration on Blood Lactate and Recovery

March 27, 2018 updated by: Joanne DiFrancisco-Donoghue, New York Institute of Technology

The Effects of Whole Body Periodic Acceleration on Blood Lactate and Recovery in Trained Individuals

Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of "passive exercise." The frequency of the translation (up to 180 cycles/minute; cpm) as well as the distance traveled (2-24mm) by the bed can be adjusted by the patient or health care professional.

The science behind the therapeutic effects of WBPA still remains largely unknown.

The objective of this study is to determine if WBPA may be used as an effective way to reduce lactic acid concentrations during recovery after intense exercise more rapidly than previously established methods.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Each visit Subjects will perform a graded treadmill exercise test. They will rest for 10 minutes. At the end of the rest period, resting vital signs (HR and BP) will be recorded as well as resting oxygen consumption (VO2). Resting capillary blood sample will be taken and analyzed by the Accutrend portable lactate analyzer to measure blood lactate levels. The cardiac and metabolic recordings will be measured by PFT GX machine (Medgraphics Ultima; St. Paul, Minnesota) that will record VO2, VCO2, RER (respiratory exchange ratio), Ve. Heart Rate will be monitored by a Polar® HR monitor. This machine is attached to a motorized treadmill with handrails. Each subject will perform a Modified Bruce Protocol which consists of a maximum of five 3-minute stages. The criteria set for peak exercise is one of the following: 1) 90% of THR; 2) a plateau of oxygen uptake is indicated; 3) if the subject is unable to maintain the pace of the treadmill; 4) an RER of over 1.0 and/or 5) a plateau in Ve (3). Additionally, the American College of Sports Medicine (ACSM) guidelines for terminating exercise testing will be followed(American College of Sports Medicine).

TIMELINE of PROCEDURES

The following recoveries will be tested on 3 separate days:

Visit 1 The subject will walk at 30-40 % of V02 max for the next 20 minutes on the treadmill after peak exercise. Blood lactate will be taken at minute 20.

Visit 2 The subject will be taken off the treadmill after a 3 minute walk and placed on the WBPA bed. The horizontal displacement will be held constant at 14 mm, and cycles/min will be held constant at 140. There is a footboard where the subjects feet are strapped in while wearing their own shoes. The platform moves in a repetitive motion from head-to- foot imparting mild periodic inertial forces in the subject's spinal axis (pGz). Blood lactate will be taken at minute 20.

Visit 3

The subject will be taken off the treadmill after a 3 minute walk and asked to sit in a chair for 20 minutes. Blood lactate will be taken at minute 20.

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • Old Westbury, New York, United States, 11758
        • New York Institute of Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Athletic Individuals who exercise regularly

Exclusion Criteria:

  • Any implantable devices
  • currently taking any medication that would effect blood pressure
  • pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: WBPA (Whole Body Accleration)
Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of "passive exercise." The frequency of the translation (up to 180 cycles/minute; cpm) as well as the distance traveled (2-24mm) by the bed can be adjusted by the patient or health care professional.
Device: Whole Body Periodic Acceleration
A bed that translates back and forth at different frequencies while the subject lies supine
Active Comparator: Active Recovery
Active recovery methods (e.g.walking, biking) have been shown to decrease blood lactate levels more than passive recovery 1,2. This arm requires subjects to walk at a low intensity as recovery.
Device: Whole Body Periodic Acceleration
A bed that translates back and forth at different frequencies while the subject lies supine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Lactate
Time Frame: 20 minutes post exercise
We will use a finger stick to collect plasma post exercise
20 minutes post exercise

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxygen Uptake
Time Frame: 20 minutes post exercsie
Oxygen uptake is measured by a subject wearing a mask that measures what they exhale.
20 minutes post exercsie

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

New York Institute of Technology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2015

Primary Completion (Actual)

May 4, 2017

Study Completion (Actual)

June 1, 2017

Study Registration Dates

First Submitted

June 23, 2015

First Submitted That Met QC Criteria

June 25, 2015

First Posted (Estimate)

June 26, 2015

Study Record Updates

Last Update Posted (Actual)

March 29, 2018

Last Update Submitted That Met QC Criteria

March 27, 2018

Last Verified

March 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BHS-1129

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acidosis, Lactic

Clinical Trials on Whole Body Periodic Acceleration

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe